Notably, stratified analysis indicated that short-term HbA1c improved significantly after treatment regardless of whether AST and ALT were normal, suggesting that DAA therapy may have additional mechanisms for regulating glucose metabolism independent of liver enzyme-indicated hepatic inflammatory activity.[37] However, the HbA1c-improving effect of DAAs at 6 months posttreatment disappeared in patients with cirrhosis or abnormal BMI. The gene discussed is GPT; the disease is Cirrhosis.